99 related articles for article (PubMed ID: 8422639)
1. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification.
Ferry JA; Linggood RM; Convery KM; Efird JT; Eliseo R; Harris NL
Cancer; 1993 Jan; 71(2):457-63. PubMed ID: 8422639
[TBL] [Abstract][Full Text] [Related]
2. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92.
van Spronsen DJ; Vrints LW; Hofstra G; Crommelin MA; Coebergh JW; Breed WP
Br J Haematol; 1997 Feb; 96(2):322-7. PubMed ID: 9029020
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin's disease in childhood: the British National Lymphoma Investigation experience (BNLI Report No 27).
Makepeace AR; Maclennan KA; Hudson GV; Jelliffe AM
Clin Radiol; 1987 Jan; 38(1):7-11. PubMed ID: 3816070
[TBL] [Abstract][Full Text] [Related]
4. Subclassification of Hodgkin's disease, nodular sclerosis type. Prognostic value?
Norum J; Wist E; Nordøy T; Stalsberg H
Anticancer Res; 1995; 15(4):1569-72. PubMed ID: 7654047
[TBL] [Abstract][Full Text] [Related]
5. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value?
Wijlhuizen TJ; Vrints LW; Jairam R; Breed WP; Wijnen JT; Bosch LJ; Crommelin MA; van Dam FE; de Koning J; Verhagen-Teulings M
Cancer; 1989 Mar; 63(6):1150-3. PubMed ID: 2917317
[TBL] [Abstract][Full Text] [Related]
6. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients.
Hess JL; Bodis S; Pinkus G; Silver B; Mauch P
Cancer; 1994 Jul; 74(2):708-14. PubMed ID: 8033052
[TBL] [Abstract][Full Text] [Related]
7. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study.
Fabian CJ; Mansfield CM; Dahlberg S; Jones SE; Miller TP; Van Slyck E; Grozea PN; Morrison FS; Coltman CA; Fisher RI
Ann Intern Med; 1994 Jun; 120(11):903-12. PubMed ID: 8172436
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
11. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for patients with Hodgkin disease in first relapse.
Healey EA; Tarbell NJ; Kalish LA; Silver B; Rosenthal DS; Marcus K; Shulman LN; Coleman CN; Canellos G; Weinstein H
Cancer; 1993 Apr; 71(8):2613-20. PubMed ID: 8453585
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease.
Baur AS; Meugé-Moraw C; Michel G; Delacrétaz F
Histopathology; 1998 Jun; 32(6):512-20. PubMed ID: 9675590
[TBL] [Abstract][Full Text] [Related]
14. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo DL; Duffey PL; Young RC; Hubbard SM; Ihde DC; Glatstein E; Phares JC; Jaffe ES; Urba WJ; DeVita VT
J Clin Oncol; 1992 Feb; 10(2):210-8. PubMed ID: 1732422
[TBL] [Abstract][Full Text] [Related]
15. Thymoma. Histologic subclassification is an independent prognostic factor.
Quintanilla-Martinez L; Wilkins EW; Choi N; Efird J; Hug E; Harris NL
Cancer; 1994 Jul; 74(2):606-17. PubMed ID: 8033040
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
17. Late relapse among patients treated for Hodgkin's disease.
Herman TS; Hoppe RT; Donaldson SS; Cox RS; Rosenberg SA; Kaplan HS
Ann Intern Med; 1985 Mar; 102(3):292-7. PubMed ID: 3970468
[TBL] [Abstract][Full Text] [Related]
18. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
[TBL] [Abstract][Full Text] [Related]
19. Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease.
Masih AS; Weisenburger DD; Vose JM; Bast MA; Armitage JO
Cancer; 1992 Jan; 69(1):228-32. PubMed ID: 1727667
[TBL] [Abstract][Full Text] [Related]
20. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
